Journals Library


Project Published

View Report

  • Latest project information

HTA - 16/51/19

Cabozantinib and vandatinib for treating advanced or metastatic medullary thyroid cancer [ID56]

Project title: Cabozantinib and vandatinib for treating advanced or metastatic medullary thyroid cancer [ID56]

Call to action: 16/51 CDF Transition Topics - Groups 1,3&6

Chief investigator: Professor Paul TappendenORCID logoorcid.org/0000-0001-6612-2332

Lead Author: Professor Paul TappendenORCID logoorcid.org/0000-0001-6612-2332

Contractor: University of Sheffield

Cost: £175,000.00

Started: September 2016 | Status: Published March 2019

PROSPERO registration: CRD42016050403

Cabozantinib and vandetanib improved progression-free survival; however, significant overall survival benefits were not demonstrated and the incremental cost-effectiveness ratio was > £138,000 per QALY gained.

Links to project documentation

The links and documents below are related to this research and are added as and when they are produced over the life of the project. The information is provided by the researchers and some may have undergone varying editorial, production and publication models, which differ to NIHR Journals Library reports. Links are to both internal (NIHR) and external websites – the NIHR is not responsible for the content of external websites.

Background & Research Questions

Why the research is being done and what is being asked

Methods

How the research is being done

Publications & Outputs

What the research produced

Outcomes & Impact

What happened as a result of the research

If you would like to receive a notification when this project is updated, please submit your email address below. This will also notify you when the Journals Library report is published.